BACKGROUND: The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML). METHODS:Subjects were children enrolled in Children's Cancer Group 2891 with AML. In phase 1 (induction), patients were randomized to intensive or standard timing. In phase 2 (consolidation), those with a family donor were allocated allogeneic stem cell transplantation (SCT); the remainder were randomized to autologous SCT or chemotherapy. This report compares infections between different treatments on an intent-to-treat basis. RESULTS: During phase 1, intensive timing was associated with more bacterial (57.7% vs 39.4%; P < .001), fungal (27.4% vs 9.9%; P < .001), and viral (14.0% vs 3.9%; P < .001) infections compared with standard timing. During phase 2, chemotherapy was associated with more bacterial (56.5% vs 40.1%; P = .005), but similar fungal (9.5% vs 6.1%; P = 1.000) and viral (4.2% vs 12.9%; P = .728) infections compared with allogeneic SCT. No differences between chemotherapy and autologous SCT infections were seen. Fatal infections were more common during intensive compared with standard timing induction (5.5% vs 0.9%; P = .004). Infectious deaths were similar between chemotherapy, autologous SCT, and allogeneic SCT. CONCLUSIONS: Prevalence of infection varies depending on the intensity and type of treatment. This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML. (c) 2009 American Cancer Society.
RCT Entities:
BACKGROUND: The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML). METHODS: Subjects were children enrolled in Children's Cancer Group 2891 with AML. In phase 1 (induction), patients were randomized to intensive or standard timing. In phase 2 (consolidation), those with a family donor were allocated allogeneic stem cell transplantation (SCT); the remainder were randomized to autologous SCT or chemotherapy. This report compares infections between different treatments on an intent-to-treat basis. RESULTS: During phase 1, intensive timing was associated with more bacterial (57.7% vs 39.4%; P < .001), fungal (27.4% vs 9.9%; P < .001), and viral (14.0% vs 3.9%; P < .001) infections compared with standard timing. During phase 2, chemotherapy was associated with more bacterial (56.5% vs 40.1%; P = .005), but similar fungal (9.5% vs 6.1%; P = 1.000) and viral (4.2% vs 12.9%; P = .728) infections compared with allogeneic SCT. No differences between chemotherapy and autologous SCT infections were seen. Fatal infections were more common during intensive compared with standard timing induction (5.5% vs 0.9%; P = .004). Infectious deaths were similar between chemotherapy, autologous SCT, and allogeneic SCT. CONCLUSIONS: Prevalence of infection varies depending on the intensity and type of treatment. This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML. (c) 2009 American Cancer Society.
Authors: W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange Journal: Blood Date: 1996-06-15 Impact factor: 22.113
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: Todd A Alonzo; Nathan L Kobrinsky; Alexander Aledo; Beverly J Lange; Allen B Buxton; William G Woods Journal: J Pediatr Hematol Oncol Date: 2002-11 Impact factor: 1.289
Authors: W G Woods; S Neudorf; S Gold; J Sanders; J D Buckley; D R Barnard; K Dusenbery; J DeSwarte; D C Arthur; B J Lange; N L Kobrinsky Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Beverly J Lange; Robert B Gerbing; James Feusner; Jeffrey Skolnik; Nancy Sacks; Franklin O Smith; Todd A Alonzo Journal: JAMA Date: 2005-01-12 Impact factor: 56.272
Authors: Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: Abdullah Alsuliman; Muharrem Muftuoglu; Ahmad Khoder; Yong-Oon Ahn; Rafet Basar; Michael R Verneris; Pawel Muranski; A John Barrett; Enli Liu; Li Li; Kate Stringaris; Darius Armstrong-James; Hila Shaim; Kayo Kondo; Nobuhiko Imahashi; Borje Andersson; David Marin; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani Journal: Blood Date: 2016-11-07 Impact factor: 22.113
Authors: Grace E Lee; Lillian Sung; Brian T Fisher; Kathleen E Sullivan; Tom McWilliams; John W Tobias; Soheil Meshinchi; Todd A Alonzo; Alan Gamis; Richard Aplenc Journal: Acta Haematol Date: 2013-11-06 Impact factor: 2.195
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167